Penile Cancer and Lymph Node Management: A Call for Standardization

Three major oncology guideline bodies disagree on lymph node staging and treatment in penile cancer, leaving surgeons without consensus at every decision point.

Journal: International Urology and Nephrology | Published: 2025-11-19 | Type: Narrative review | PMID: 41258991 Authors: Aveta A et al., primarily from Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Naples — Italy's national cancer institute, a high-volume center Funding/COI: Funding not disclosed; authors declare no competing interests

Summary

Penile cancer is rare enough that no single center accumulates enough cases to run a definitive RCT, so lymph node management has been driven by expert consensus — and the experts don't agree. This review lays out where NCCN, ESMO-EURACAN, and EAU-ASCO converge and diverge on staging and surgical treatment of inguinal and pelvic lymph nodes. The honest conclusion: the gaps are wide, the evidence is thin, and what a patient gets depends heavily on where they're treated.

Claims

• Physical examination alone for lymph node staging (cN0) misses micrometastases in up to 25% of obese patients
• Only 20–25% of cN0 patients harbor occult nodal metastases, meaning surgical staging overtreats 75–80% of this group
• All three guidelines recommend surveillance for low-risk cN0 disease; they diverge on intermediate-risk management — EAU-ASCO allows surveillance for T1a G2, while ESMO-EURACAN and NCCN favor more aggressive staging
• Dynamic sentinel node biopsy (DSNB) achieves high diagnostic accuracy with the lowest complication rates in cN0 disease, but performance is strongly volume-dependent
• Video-endoscopic inguinal lymphadenectomy (VEIL and robot-assisted RA-VEIL) show equivalent diagnostic accuracy to open ILND with potentially fewer wound complications, but comparative oncological outcome data are limited to cN0 cases
• Pelvic lymph node dissection is indicated when ≥3 inguinal nodes are positive or extracapsular spread is present — the strongest predictors of pelvic involvement — though this threshold is not uniformly adopted across guidelines
• cN3 disease requires multimodal therapy: neoadjuvant chemotherapy followed by surgical resection when feasible

Study Quality

This is a narrative comparison of three existing guidelines, not original research. There is no systematic literature search, no PRISMA diagram, no predefined inclusion criteria, and no quantitative synthesis. The authors acknowledge this explicitly — the paper is an organizational exercise, not a meta-analysis. It is useful as a clinical reference document precisely because it lays out the guideline table side-by-side, but it generates no new evidence and its conclusions are entirely derivative.

The underlying evidence base is weak by the authors' own admission: most recommendations across all three guidelines carry level III evidence, and "expert opinion" does heavy lifting throughout. That's not a failure of this review — it accurately reflects the state of the field for a cancer with an estimated global incidence of roughly 1 per 100,000 men.

Red Flags

• No systematic search methodology; selection of cited studies is not transparent
• No grading of the underlying evidence beyond what the guidelines themselves provide
• All corresponding authors are from one Italian cancer center — potential for institutional perspective shaping emphasis
• The guidelines being compared are themselves heterogeneous in their methodological rigor and update cycles, making direct comparison structurally uneven
• Funding source not disclosed; unusual for a review of this type

Strengths

• Side-by-side guideline comparison table (Table 2) is genuinely useful for clinicians navigating three inconsistent documents
• Authors are candid about the evidence vacuum: they don't overclaim
• Explicitly identifies where institutional volume and resource availability drive guideline divergence — a structural problem that most guideline documents paper over
• Covers the full staging and management pathway from cN0 through cN3 and pelvic disease in one place

Verdict

A useful triage document, not a scientific advance. If you need to know where NCCN, ESMO-EURACAN, and EAU-ASCO agree and disagree on penile cancer lymph node management, this paper saves you from reading three lengthy guidelines. If you're hoping for new data, there isn't any. The real finding is buried in the methods section: penile cancer is so rare that evidence-based guidelines are largely aspirational, and three major guideline bodies have arrived at meaningfully different recommendations from the same thin evidence base. That's the story. The call for "collaborative prospective trials" in the conclusion is correct and has been made by every penile cancer review for the past decade.